高尔基体
液泡
细胞病理学
内质网
内体
细胞生物学
溶酶体
小泡
细胞器
舱室(船)
溶酶体贮存病
粘多糖病Ⅰ
生物
细胞室
细胞质
化学
医学
病理
细胞
生物化学
疾病
酶
细胞内
酶替代疗法
膜
海洋学
地质学
细胞学
作者
Kinga Molnár,Julianna Kobolák,András Dinnyés
出处
期刊:Biologia futura
[Springer Science+Business Media]
日期:2021-11-27
卷期号:73 (1): 31-42
被引量:2
标识
DOI:10.1007/s42977-021-00107-y
摘要
Abstract Lysosome (L), a hydrolytic compartment of the endo-lysosomal system (ELS), plays a central role in the metabolic regulation of eukaryotic cells. Furthermore, it has a central role in the cytopathology of several diseases, primarily in lysosomal storage diseases (LSDs). Mucopolysaccharidosis II (MPS II, Hunter disease) is a rare LSD caused by idunorate-2-sulphatase (IDS) enzyme deficiency. To provide a new platform for drug development and clarifying the background of the clinically observed cytopathology, we established a human in vitro model, which recapitulates all cellular hallmarks of the disease. Some of our results query the traditional concept by which the storage vacuoles originate from the endosomal system and suggest a new concept, in which endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and RAB2/LAMP positive Golgi (G) vesicles play an initiative role in the vesicle formation. In this hypothesis, Golgi is not only an indirectly affected organelle but enforced to be the main support of vacuole formation. The purposes of this minireview are to give a simple guide for understanding the main relationships in ELS, to present the storage vacuoles and their relation to ELS compartments, to recommend an alternative model for vacuole formation, and to place the Golgi in spotlight of MPS II cytopathology.
科研通智能强力驱动
Strongly Powered by AbleSci AI